WallStreetZenWallStreetZen

NYSE: NVS
Novartis Ag Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsDividendOwnership

Be the first to know when Wall Street analysts revise their NVS stock forecasts and price targets.

Forecast return on equity

Is NVS forecast to generate an efficient return?
Company
N/A
Industry
13.55%
Market
30.08%

Forecast return on assets

Is NVS forecast to generate an efficient return on assets?
Company
N/A
Industry
5.57%

NVS revenue forecast

What is NVS's revenue in the next 3 years based on estimates from 3 analysts?
Avg 1 year Forecast
$45.3B-13.37%
Avg 2 year Forecast
$46.4B-11.34%
Avg 3 year Forecast
$48.8B-6.73%
NVS's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

NVS earnings growth forecast

How is NVS forecast to perform vs Drug Manufacturers - General companies and vs the US market?
Company
26.24%
Industry
32.44%
Market
17.67%
NVS's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Industry Forecast
NVS's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Market Forecast
NVS's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Savings Rate Forecast

NVS revenue growth forecast

How is NVS forecast to perform vs Drug Manufacturers - General companies and vs the US market?
Company
-2.45%
Industry
4.25%
Market
7.51%
NVS's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
NVS's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

NVS vs General Drug Manufacturer Stocks

TickerPricePrice TargetUp/downsideConsensus
NVS$97.90N/AN/A
AZN$64.59$81.50+26.18%Strong Buy
PFE$30.47$40.67+33.47%Buy
ABBV$142.39$171.67+20.56%Strong Buy
AMGN$269.64$275.73+2.26%Buy
View Top General Drug Manufacturer Stocks

Novartis Ag Stock Forecast FAQ

What is NVS's revenue growth forecast for 2023-2025?

(NYSE: NVS) Novartis Ag's forecast annual revenue growth rate of -2.45% is not forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 4.25%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 7.51%.

Novartis Ag's revenue in 2023 is $52,323,000,000.On average, 3 Wall Street analysts forecast NVS's revenue for 2023 to be $93,171,149,015,000, with the lowest NVS revenue forecast at $91,274,210,285,000, and the highest NVS revenue forecast at $94,546,833,500,000. On average, 3 Wall Street analysts forecast NVS's revenue for 2024 to be $95,356,844,385,000, with the lowest NVS revenue forecast at $94,016,678,940,000, and the highest NVS revenue forecast at $97,512,920,000,000.

In 2025, NVS is forecast to generate $100,308,996,095,000 in revenue, with the lowest revenue forecast at $99,446,837,175,000 and the highest revenue forecast at $101,105,975,110,000.

If you're new to stock investing, here's how to buy Novartis Ag stock.

What is NVS's forecast return on assets (ROA) for 2023-2026?

(NYSE: NVS) forecast ROA is N/A, which is lower than the forecast US Drug Manufacturers - General industry average of 5.57%.

What is NVS's forecast return on equity (ROE) for 2023-2026?

(NYSE: NVS) forecast ROE is N/A, which is considered weak.
©2023 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.